Psilocybin microdosing is often associated with the hope of antidepressant effects, increased concentration, creativity, emotional balance, or better coping with everyday life. But who is it even suitable for? What known risks exist, and who should be particularly careful, or first seek medical advice?
The scientific data is currently limited, and we often have to rely on empirical experiences. But first:
What is meant by psilocybin microdosing?
Microdosing involves consuming very small amounts of psilocybin-containing mushrooms or truffles. The intended effect is to avoid producing clearly noticeable psychedelic effects.
A truly subperceptual dose is one in which no conscious changes in perception or experience occur. However, the subjective absence of such changes does not automatically mean that attention, responsiveness, and other cognitive functions remain unaffected. When in doubt, it is always best to err on the side of caution: take less.
An important distinction is therefore between a barely noticeable effect and demonstrably unchanged performance. The two are not the same; even very small doses can, for example, reduce performance in some areas while increasing it in others.
Are the frequently mentioned dosages really microdoses?
On the internet, amounts between 0.1 and 0.5 grams of dried magic mushrooms are sometimes referred to as a microdose. Such blanket statements are problematic because they do not reliably describe the actual amount of active ingredient. For most people, 0.5g is far too much for a microdose.
The psilocybin and psilocin content can vary considerably depending on the mushroom species, individual specimen, origin, and processing. There are also major differences in water content between fresh and dried mushrooms.
Therefore, an amount that causes barely noticeable effects in one person may cause significant changes in perception or experience in another. Even mild effects can affect concentration, judgment, or responsiveness.
An amount referred to as a microdose on the internet is therefore no guarantee of a subperceptual effect. As soon as changes in perception, confusion, drowsiness, or other noticeable impairments occur, it should not be considered suitable for everyday microdosing.
[Modern Psychedelic Microdosing Research on Mental Health – Systematic Review (2024)](https://pubmed.ncbi.nlm.nih.gov/38228068/ )
Sobriety and personal responsibility in everyday life
Anyone who consumes psilocybin is responsible for their own behavior and the safety of others. This also applies to supposedly very small amounts.
Possible impairments should not be underestimated, especially in road traffic, when operating machinery, working with dangerous tools, and in other activities that require full attention.
Personal experience with a substance also offers no guarantee that its effects will be the same upon later consumption. People change, and many need a LOWER microdose after a few weeks or months of microdosing than they did at the beginning. We have learned this from hundreds of experience reports, and although it has not yet been clinically proven, it should be mentioned to avoid misunderstandings. "0.1g was always my dose!" should carry no more weight than the feeling that it might actually be a little less.
Anyone who must reliably ensure full attention and responsiveness should therefore not rely on a self-assessed microdose as a basis for safety. If noticeable effects or uncertainty occur, the rule is: do not participate in road traffic or engage in dangerous activities.
How safe is psilocybin?
Psilocybin has been intensively studied in clinical trials. A systematic review with meta-analysis on therapeutic doses of psilocybin, published in 2024 in *JAMA Network Open*, showed that serious adverse events were rare in the studies examined, even at high doses.
These results are generally encouraging for the scientific research of the substance. However, they do not allow for a blanket statement that psilocybin is safe in every application or for every person. For example, at high doses on the highway, it is definitely not safe.
With natural raw products, the active ingredient concentration is also not reliably standardized. This means that the actual amount ingested may differ from the expected amount. This is especially important to consider if you do not grow your own mushrooms but receive them as a gift, for example. In addition, there are differences in individual sensitivity, possible interactions with medications, and limited data on repeated microdosing over long periods.
* Yerubandi et al. (2024): [Acute Adverse Effects of Therapeutic Doses of Psilocybin – Systematic Review and Meta-Analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC11007582/ )
Who should avoid psilocybin microdosing?
Certain groups of people have particular risk factors. For them, independent consumption is not fundamentally impossible, but it requires extensive research and particularly low dosages.
It is always best to consult a doctor or therapist who ideally is also familiar with the topic.
1. People with a history of psychosis
People who have previously experienced psychosis or currently suffer from psychotic symptoms are among the particularly vulnerable groups. Psychedelic substances can induce intense psychological reactions. In correspondingly predisposed individuals, there is a concern that symptoms may be triggered or worsened.
A family history of certain psychotic disorders can also be relevant when assessing risk.
2. People with bipolar disorder
Particular caution is required with bipolar disorder, especially in cases of previous manic or psychotic episodes. Changes in experience and mood can be problematic in this context. Therefore, independent consumption of psilocybin is not recommended.
3. People taking psychotropic medications
The simultaneous consumption of psilocybin and psychotropic medications may be associated with risks. Interactions depend on the respective active ingredient, the dosage, other medications, and the individual health situation.
Particular attention should be paid to:
MAO inhibitors: These medications can cause interactions with psychoactive substances. The combination should not be tried without preparation.
Antidepressants: Depending on the active ingredient, they may alter the effects of psilocybin. The risks are not the same for all preparations and have not been conclusively determined.
Antipsychotics and other psychotropic medications: Here too, effects and side effects can influence each other.
Anyone taking psychotropic medications should ideally not combine psilocybin without a professional medical assessment. Medications should not be hastily discontinued or changed on their own to enable microdosing.
4. Minors
The effects of psilocybin microdosing in children and adolescents have not been sufficiently studied. Due to brain development, psychological maturation, and the insufficient data, even adults should not blindly turn to microdosing as an unknown but promising solution. This is not only risky, but also deprives minors of the opportunity to discuss it.
5. Pregnant and breastfeeding women
There is insufficient safety data on the use of psilocybin during pregnancy and breastfeeding. If interested in experience reports, there is a website that collects experience reports called "Mothers of mushroom".
6. People with relevant physical illnesses
Physical illnesses can also play a role. Psilocybin can temporarily increase blood pressure and heart rate. People with severe or poorly controlled cardiovascular diseases should therefore exercise particular caution and refrain from independent consumption.
Is microdosing recommended for healthy adults?
For healthy adults without known particular risk factors, the individual risk assessment is different from that of the mentioned risk groups. However, this does not mean that microdosing can be generally recommended.
Research into possible benefits for mood, concentration, creativity, and psychological well-being has so far provided no convincing, consistent picture. Positive experience reports exist and are documented both on this website and all over the internet (YouTube, Reddit, Instagram, etc.).
These are empirical experience reports and are not to be equated with "It works for everyone, always."
How should the physical safety profile of psilocybin be assessed?
Physical toxicity: Clinical studies have so far provided no consistent evidence of pronounced direct organ toxicity of psilocybin under controlled conditions.
Psilocybin differs in its toxicological profile from many other psychoactive substances. Clinical studies under controlled conditions have so far provided no consistent evidence of pronounced direct damage to internal organs by the active ingredient alone. The known acute risks are rather the psychoactive effect, temporary physical reactions, and possible psychological complications in correspondingly predisposed individuals.
This is to be distinguished from the possible neurobiological effects of psilocybin. Research results indicate that the substance influences neuroplasticity processes. Possible effects on cellular aging processes are also being investigated and have so far been positive; human cells lived 72% longer in vitro after the administration of psilocybin in vitro. These research approaches are promising, but not yet conclusive.
Cellular aging: A study published in 2025 reported an extended lifespan of human cells in the laboratory and an increased lifespan of old mice after psilocybin treatment. This is an interesting finding, but not yet proof that psilocybin slows down the aging process in humans.
Neuroplasticity: There is promising research on changes in neuronal structures and connections. However, the results from animal models and initial human studies are not equivalent to proven health benefits from microdosing.
Annual Reviews